WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Exchange
Industry
Zen Score
Market Cap
Price
1d %
EBITDA
P/E
D/E
ELYM
ELIEM THERAPEUTICS INC
NASDAQ
Biotechnology
$101.45M$3.66-2.40%-$34.71M-2.82x0.03
EPIX
ESSA PHARMA INC
NASDAQ
Biotechnology
$276.49M$6.25-2.34%-$25.69M-10.59x0.03
SLNO
SOLENO THERAPEUTICS INC
NASDAQ
Biotechnology
$1.28B$39.34-1.99%-$36.71M-16.67x0.15
TYRA
TYRA BIOSCIENCES INC
NASDAQ
Biotechnology
$840.34M$16.00-2.32%-$68.78M-9.88x0.11
THRD
THIRD HARMONIC BIO INC
NASDAQ
Biotechnology
$461.29M$11.332.53%-$30.23M-14.53x0.03
ENTX
ENTERA BIO LTD
NASDAQ
Biotechnology
$73.45M$2.07-6.76%-$8.80M-6.68x0.13
SYRS
SYROS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$134.12M$5.07-1.36%-$157.12M-0.87x9.09
CMPX
COMPASS THERAPEUTICS INC
NASDAQ
Biotechnology
$203.63M$1.48-2.63%-$40.60M-4.48x0.06
ABOS
ACUMEN PHARMACEUTICALS INC
NASDAQ
Biotechnology
$191.05M$3.180.63%-$51.61M-2.94x0.16
AURA
AURA BIOSCIENCES INC
NASDAQ
Biotechnology
$351.48M$7.10-1.66%-$73.14M-3.68x0.13
DSGN
DESIGN THERAPEUTICS INC
NASDAQ
Biotechnology
$206.20M$3.65-0.27%-$66.29M-3.07x0.04
BCRX
BIOCRYST PHARMACEUTICALS INC
NASDAQ
Biotechnology
$867.89M$4.21-3.88%-$116.34M-3.57x-2.14
ERAS
ERASCA INC
NASDAQ
Biotechnology
$284.81M$1.88-2.59%-$121.31M-2.27x0.25
NUVB
NUVATION BIO INC
NYSE
Biotechnology
$582.66M$2.66-0.75%-$75.65M-7.60x0.03
PTIX
PROTAGENIC THERAPEUTICS INC
NASDAQ
Biotechnology
$7.26M$1.644.33%-$4.86M-1.42x0.18
WVE
WAVE LIFE SCIENCES LTD
NASDAQ
Biotechnology
$612.64M$5.01-1.38%-$48.98M-9.28x5.74
AFMD
AFFIMED NV
NASDAQ
Biotechnology
$74.31M$4.88-8.79%-$114.03M-0.63x0.68
ONVO
ORGANOVO HOLDINGS INC
NASDAQ
Biotechnology
$10.04M$1.000.00%-$18.82M-0.46x0.44
GERN
GERON CORP
NASDAQ
Biotechnology
$1.95B$3.582.29%-$174.78M-11.19x0.59
TNGX
TANGO THERAPEUTICS INC
NASDAQ
Biotechnology
$828.13M$7.76-0.13%-$95.59M-7.19x0.59
APM
APTORUM GROUP LTD
NASDAQ
Biotechnology
$28.81M$5.561.09%-$11.65M-1.51x0.08
PRAX
PRAXIS PRECISION MEDICINES INC
NASDAQ
Biotechnology
$677.01M$51.144.71%-$122.01M-2.74x0.26
ORGS
ORGENESIS INC
NASDAQ
Biotechnology
$17.24M$0.50-3.28%-$50.83M0.26x-1.69
IOVA
IOVANCE BIOTHERAPEUTICS INC
NASDAQ
Biotechnology
$3.27B$11.71-1.26%-$414.39M-6.20x0.34
GNLX
GENELUX CORP
NASDAQ
Biotechnology
$92.69M$3.45-0.86%-$27.63M-2.97x0.43
SCPH
SCPHARMACEUTICALS INC
NASDAQ
Biotechnology
$162.24M$4.50-2.39%-$46.06M-3.17x1.54
XNCR
XENCOR INC
NASDAQ
Biotechnology
$1.16B$19.023.54%-$108.78M-9.14x0.42
ABVX
ABIVAX SA
NASDAQ
Biotechnology
$999.94M$15.890.19%-$129.52M-4.26x0.67
CTMX
CYTOMX THERAPEUTICS INC
NASDAQ
Biotechnology
$110.39M$1.63-2.98%$9.23M-163.00x-5.25
RCUS
ARCUS BIOSCIENCES INC
NYSE
Biotechnology
$1.40B$15.43-0.45%-$285.00M-3.72x1.37
INMB
INMUNE BIO INC
NASDAQ
Biotechnology
$191.44M$10.624.73%-$30.01M-6.36x0.51
MTNB
MATINAS BIOPHARMA HOLDINGS INC
NYSEMKT
Biotechnology
$39.58M$0.180.55%-$22.00M-1.65x0.30
CDXC
CHROMADEX CORP
NASDAQ
Biotechnology
$256.05M$3.400.00%-$3.23M-48.57x0.93
CHRS
COHERUS BIOSCIENCES INC
NASDAQ
Biotechnology
$227.68M$2.02-7.34%-$191.46M-0.80x-4.26
MGX
METAGENOMI INC
NASDAQ
Biotechnology
$252.94M$6.75-3.98%-$51.81M-0.34x-1.10
PHAT
PHATHOM PHARMACEUTICALS INC
NASDAQ
Biotechnology
$533.31M$9.120.66%-$159.05M-2.32x-6.69
PRQR
PROQR THERAPEUTICS NV
NASDAQ
Biotechnology
$163.52M$2.01-0.50%-$26.33M-5.29x2.33
HRTX
HERON THERAPEUTICS INC
NASDAQ
Biotechnology
$398.37M$2.65-5.36%-$107.16M-3.31x-7.55
IBRX
IMMUNITYBIO INC
NASDAQ
Biotechnology
$3.25B$4.82-12.20%-$429.41M-4.19x-1.86
OABI
OMNIAB INC
NASDAQ
Biotechnology
$534.09M$4.56-1.72%-$44.87M-8.94x0.19
FTRE
FORTREA HOLDINGS INC
NASDAQ
Biotechnology
$3.33B$37.250.84%$194.70M-931.25x1.51
BYSI
BEYONDSPRING INC
NASDAQ
Biotechnology
$94.81M$2.436.11%N/A-3.42x-2.63
SYBX
SYNLOGIC INC
NASDAQ
Biotechnology
$21.78M$1.87-2.09%-$51.97M-0.21x0.77
FBIO
FORTRESS BIOTECH INC
NASDAQ
Biotechnology
$34.43M$1.79-1.10%-$36.73M-0.21x7.36
ADAP
ADAPTIMMUNE THERAPEUTICS PLC
NASDAQ
Biotechnology
$267.10M$1.08-5.26%-$102.70M-2.00x6.15
ELAB
ELEVAI LABS INC
NASDAQ
Biotechnology
$10.47M$0.600.67%-$4.27M-1.51x0.36
NBTX
NANOBIOTIX SA
NASDAQ
Biotechnology
$278.09M$5.903.33%-$25.02M-5.08x-51.95
AUTL
AUTOLUS THERAPEUTICS PLC
NASDAQ
Biotechnology
$1.12B$4.21-6.03%-$152.71M-3.51x2.37
TSBX
TURNSTONE BIOLOGICS CORP
NASDAQ
Biotechnology
$70.91M$3.070.33%-$52.69M-0.64x0.14
NMRA
NEUMORA THERAPEUTICS INC
NASDAQ
Biotechnology
$1.52B$9.59-6.89%-$231.63M-2.64x0.06
IRON
DISC MEDICINE INC
NASDAQ
Biotechnology
$673.79M$27.301.11%-$75.94M-7.98x0.07
OLMA
OLEMA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$567.53M$10.151.50%-$94.98M-4.74x0.09
INZY
INOZYME PHARMA INC
NASDAQ
Biotechnology
$271.80M$4.400.00%-$66.51M-3.21x0.43
IVVD
INVIVYD INC
NASDAQ
Biotechnology
$253.94M$2.13-6.17%-$196.62M-1.18x0.29
ATXI
AVENUE THERAPEUTICS INC
NASDAQ
Biotechnology
$4.16M$0.09-29.85%-$10.38M-0.10x0.76
IPA
IMMUNOPRECISE ANTIBODIES LTD
NASDAQ
Biotechnology
$32.10M$1.220.00%-$7.05M-2.96x0.58
IMUX
IMMUNIC INC
NASDAQ
Biotechnology
$111.51M$1.240.00%-$93.50M-0.59x0.88
SGMT
SAGIMET BIOSCIENCES INC
NASDAQ
Biotechnology
$133.08M$4.17-2.57%-$27.74M-1.57x0.06
IMAB
I-MAB
NASDAQ
Biotechnology
$149.62M$1.810.56%N/A-0.79x0.52
SRZN
SURROZEN INC
NASDAQ
Biotechnology
$28.69M$8.97-0.44%-$39.86M-0.42x0.22
THTX
THERATECHNOLOGIES INC
NASDAQ
Biotechnology
$62.53M$1.36-1.45%-$1.41M-3.30x-3.93
RLMD
RELMADA THERAPEUTICS INC
NASDAQ
Biotechnology
$116.47M$3.86-1.28%-$98.79M-1.18x0.14
HEPA
HEPION PHARMACEUTICALS INC
NASDAQ
Biotechnology
$7.22M$1.32-11.41%-$49.26M-0.11x1.49
GOVX
GEOVAX LABS INC
NASDAQ
Biotechnology
$3.35M$1.540.00%-$25.89M-0.11x0.61
QNRX
QUOIN PHARMACEUTICALS LTD
NASDAQ
Biotechnology
$2.33M$0.63-4.24%-$8.58MN/A1.15
EWTX
EDGEWISE THERAPEUTICS INC
NASDAQ
Biotechnology
$1.50B$16.112.94%-$98.43M-10.26x0.07
FBRX
FORTE BIOSCIENCES INC
NASDAQ
Biotechnology
$26.20M$0.72-2.57%-$31.47M-0.72x0.10
ONCT
ONCTERNAL THERAPEUTICS INC
NASDAQ
Biotechnology
$25.29M$8.55-2.51%-$39.31M-0.64x0.22
RCKT
ROCKET PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.14B$23.63-0.17%-$236.62M-8.09x0.15
VIGL
VIGIL NEUROSCIENCE INC
NASDAQ
Biotechnology
$102.17M$2.774.53%-$80.88M-1.30x0.21
NNVC
NANOVIRICIDES INC
NYSEMKT
Biotechnology
$13.55M$1.150.88%-$8.55M-1.42x0.08
VKTX
VIKING THERAPEUTICS INC
NASDAQ
Biotechnology
$6.54B$65.070.22%-$85.60M-71.51x0.06
ELEV
ELEVATION ONCOLOGY INC
NASDAQ
Biotechnology
$188.77M$3.88-10.19%-$45.64M-2.90x0.63
RAPT
RAPT THERAPEUTICS INC
NASDAQ
Biotechnology
$274.90M$7.90-1.25%-$113.25M-2.59x0.18
VRPX
VIRPAX PHARMACEUTICALS INC
NASDAQ
Biotechnology
$3.71M$3.170.32%-$15.19M-0.24x3.98
CRVS
CORVUS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$74.05M$1.51-1.31%-$26.88M-2.70x0.18
REPL
REPLIMUNE GROUP INC
NASDAQ
Biotechnology
$388.58M$6.33-1.40%-$200.44M-2.00x0.26
RNAC
CARTESIAN THERAPEUTICS INC
NASDAQ
Biotechnology
$111.85M$20.720.63%-$233.28M-0.42x-1.01
CRGX
CARGO THERAPEUTICS INC
NASDAQ
Biotechnology
$738.06M$18.75-1.32%-$92.85M-1.13x0.12
XERS
XERIS BIOPHARMA HOLDINGS INC
NASDAQ
Biotechnology
$247.20M$1.76-1.12%-$23.74M-3.91x-48.57
COGT
COGENT BIOSCIENCES INC
NASDAQ
Biotechnology
$679.59M$6.54-6.03%-$188.82M-2.70x0.22
TRML
TOURMALINE BIO INC
NASDAQ
Biotechnology
$395.21M$15.412.12%-$41.97M-1.74x0.03
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ
Biotechnology
$2.71B$42.43-1.90%-$43.97M-58.12x0.03
RZLT
REZOLUTE INC
NASDAQ
Biotechnology
$114.52M$2.891.05%-$56.28M-2.63x0.11
CARM
CARISMA THERAPEUTICS INC
NASDAQ
Biotechnology
$69.79M$1.68-1.18%-$80.55M-0.65x2.38
DRTS
ALPHA TAU MEDICAL LTD
NASDAQ
Biotechnology
$173.48M$2.49-0.40%-$21.53M-5.93x0.27
ATHE
ALTERITY THERAPEUTICS LTD
NASDAQ
Biotechnology
$13.06M$2.339.39%N/A-1.04x0.26
SRRK
SCHOLAR ROCK HOLDING CORP
NASDAQ
Biotechnology
$1.10B$14.09-4.73%-$155.82M-7.08x0.38
SNTI
SENTI BIOSCIENCES INC
NASDAQ
Biotechnology
$12.86M$0.28-6.33%-$65.63M-0.18x0.79
CTNM
CONTINEUM THERAPEUTICS INC
NASDAQ
Biotechnology
N/A$15.930.13%$4.96M11.71x-0.08
COYA
COYA THERAPEUTICS INC
NASDAQ
Biotechnology
$122.30M$8.414.86%-$7.24M-10.65x0.16
ZURA
ZURA BIO LTD
NASDAQ
Biotechnology
$144.30M$3.31-4.89%-$60.36M-1.58x0.36
TARA
PROTARA THERAPEUTICS INC
NASDAQ
Biotechnology
$32.24M$2.82-6.00%-$40.08M-0.79x0.16
APVO
APTEVO THERAPEUTICS INC
NASDAQ
Biotechnology
$364.36k$0.68-7.20%-$16.84M-0.01x1.03
ELDN
ELEDON PHARMACEUTICALS INC
NASDAQ
Biotechnology
$48.88M$1.97-8.80%-$39.95M-1.20x0.07
ACHL
ACHILLES THERAPEUTICS PLC
NASDAQ
Biotechnology
$32.21M$0.780.38%-$64.46M-0.45x0.13
GOSS
GOSSAMER BIO INC
NASDAQ
Biotechnology
$159.71M$0.71-4.07%-$161.92M-0.60x3.97
INTS
INTENSITY THERAPEUTICS INC
NASDAQ
Biotechnology
$54.70M$3.99-1.48%-$10.09M-2.89x0.31
ADTX
ADITXT INC
NASDAQ
Biotechnology
$3.95M$2.374.41%-$27.64M-0.02x1.78
ADCT
ADC THERAPEUTICS SA
NYSE
Biotechnology
$394.49M$4.78-3.82%-$151.36M-1.63x-3.39

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -31.24% over the past year, underperforming other biotech stocks by -7 percentage points.

Incyte has an average 1 year price target of $74.69, an upside of 44.36% from Incyte's current stock price of $51.74.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 23.08% have issued a Strong Buy rating, 23.08% have issued a Buy, 53.85% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -9.81% over the past year, overperforming other biotech stocks by 14 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 27.72% from Harmony Biosciences Holdings's current stock price of $29.23.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock lose -1.69% over the past year, overperforming other biotech stocks by 22 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 170.81% from Voyager Therapeutics's current stock price of $7.57.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 14.18%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 53.68%, which is 40 percentage points higher than the biotech industry average of 14.18%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.09%, which is -13 percentage points lower than the biotech industry average of 14.18%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -0.75% in the last day, and down -1% over the last week. Avenue Therapeutics was the among the top losers in the biotechnology industry, dropping -29.85% yesterday.

Avenue Therapeutics shares are trading lower after the company announced a reverse stock split.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -21.91% in the past year. It has overperformed other stocks in the biotech industry by 2 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has dropped -1.69% in the past year. It has overperformed other stocks in the biotech industry by 22 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -31.24% in the past year. It has underperformed other stocks in the biotech industry by -7 percentage points.

Are biotech stocks a good buy now?

49.32% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 88.37% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 15.69x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.